Allogene Therapeutics, Inc. 2024-2025 Proxy Voting Records

Description as filed by funds: Election of Directors: Arie Belldegrun, M.D.

Allogene Therapeutics, Inc.’s own tally for this item (“Elect Director: Arie Belldegrun, M.D.”): 150,891,245 for, 6,474,169 withheld, per its Form 8-K filed June 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three persons listed below as Class I Directors, each to serve until the Company's 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 26,989,897 for, 1,883,941 withheld.

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

Description as filed by funds: Election of Directors: David Chang, M.D., Ph.D.

Allogene Therapeutics, Inc.’s own tally for this item (“Elect Director: David Chang, M.D., Ph.D.”): 153,721,017 for, 3,644,397 withheld, per its Form 8-K filed June 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three persons listed below as Class I Directors, each to serve until the Company's 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 28,301,714 for, 572,124 withheld.

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

Description as filed by funds: Election of Directors: Elizabeth Barrett

Allogene Therapeutics, Inc.’s own tally for this item (“Elect Director: Elizabeth Barrett”): 131,435,760 for, 25,929,654 withheld, per its Form 8-K filed June 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three persons listed below as Class I Directors, each to serve until the Company's 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 84% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 11,152,293 for, 17,721,545 withheld.

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.

Allogene Therapeutics, Inc.’s own tally for this item (“2. Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers”): 139,947,868 for, 14,233,309 against — passed, per its Form 8-K filed June 23, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement for the Annual Meeting.”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 46 managers: 16,588,976 for, 12,284,862 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 109 managers: 65,175,172 for, 12,535,929 against, 2,920,787 abstained. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.

Allogene Therapeutics, Inc.’s own tally for this item (“3. Ratification of the Selection of Independent Registered Public Accounting Firm”): 190,111,256 for, 414,604 against — passed, per its Form 8-K filed June 23, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending …”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 28,873,838 for.

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.